Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myelomaKatja Weisel, Paul G. Richardson, Filiz Vural et al.|Leukemia & lymphoma/Leukemia and lymphoma|2020Cited by 13
Durable Symptom Improvement for Patients with Non-Transfusion Dependent Thalassemia Treated with Luspatercept: Patient-Reported Outcomes from the BEYOND StudyKhaled M. Musallam, Kevin H.M. Kuo, Alì Taher et al.|Blood|2023Cited by 6
Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone - Results from the Phase 3 Optimismm StudyKatja Weisel, Paul G. Richardson, Meletios Α. Dimopoulos et al.|Blood|2018Cited by 1